AstraZeneca plc (ADR) (AZN), Eli Lilly & Co. (LLY): The Diabetes Pipeline With a Clog

Page 1 of 2

Eli Lilly & Co. (NYSE:LLY)Big pharma placed its bets on a new class of diabetes drugs called SGLT2. Last year, buzz surrounded late-stage projects from Johnson and Johnson (NYSE:JNJ), Eli Lilly & Co. (NYSE:LLY), and the partnership of Bristol Myers Squibb Co. (NYSE:BMY) and AstraZeneca plc (ADR) (NYSE:AZN). But the path to market proved tricky.

Johnson and Johnson (NYSE:JNJ)’s Invokana earlier this year became the first SGLT2 approved in the United States. Bristol Myers Squibb Co. (NYSE:BMY) and AstraZeneca plc (ADR) (NYSE:AZN)’s Forxiga was the first out in Europe but remains stuck in the Food and Drug Administration’s pipes.  Could Eli Lilly & Co. (NYSE:LLY)’s empagliflozin follow Invokana to the U.S. market — or will it become stuck behind Forxiga?

And how much does an SGLT2 win even matter to these companies?

Bumpy road for SGLT2s

SGLT2s were hyped because they’re insulin-independent, which means they can fit into a combo therapy with insulin without risking counteraction. The class also has the potential to become a blockbuster market, with sales of Invokana predicted to reach $1 billion by 2018.

But the FDA has become notoriously skittish when it comes to the safety of diabetes drugs.

Bristol Myers Squibb Co. (NYSE:BMY) and AstraZeneca plc (ADR) (NYSE:AZN)’s SGLT2 received European approval under the name Forxiga, and brought in $3 million in the first quarter. But an FDA approval hangs just out of reach due to concerns of cancer risks. An advisory committee voted 9-6 that the safety and efficacy data wasn’t sufficient to support an approval. Then the FDA issued a complete response letter requesting more data.

Johnson and Johnson (NYSE:JNJ)’s Invokana didn’t show any of Forxiga’s cancer risks. But the drug did need to undergo long-term cardiovascular trials, which should wrap up in 2015. And coming first into the U.S. could provide Johnson with the market advantage.

Which path will Eli Lilly & Co. (NYSE:LLY)’s pipeline contender follow?

Lilly’s contender

Eli Lilly & Co. (NYSE:LLY) provided a glimpse at empagliflozin’s late-stage data during the American Diabetes Association meeting last month. Empagliflozin went up against placebo and showed improvements in reducing blood sugar, blood pressure, and weight. But the drug also showed an increased chance of genital infection due to the glucose that leaves the body through urine.

There’s a good chance the FDA won’t issue a denial or complete response letter based solely on the risk of genital infection. That’s not quite in the same ballpark as Forxiga’s cancer concerns. A cardiovascular safety requirement is more likely, but could be met with data from the late-stage trials.

It’s a fool’s errand these days to guess which way the FDA will rule on a diabetes drug’s safety. But we should have an idea of the agency’s direction soon; Lilly filed its new drug application in March.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!